XORTX to Present at BIO International Convention 2022
June 13, 2022 08:55 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX to Present at LD Micro Invitational 2022
June 08, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Welcomes New Member to the Board of Directors and Appoints Chair
June 06, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX to Present at H. C. Wainwright Global Investment Conference 2022
May 25, 2022 08:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, May 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmaceutical company focused on...
XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease
May 05, 2022 07:00 ET
|
XORTX Therapeutics Inc.
● FDA Provides All Clear Notification for IND and Bridging Pharmacokinetics Study ● CALGARY, Alberta, May 05, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:...
XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial
May 03, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, May 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing...
XORTX Receives Small and Medium Enterprise Status for the European Union
April 20, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing...
XORTX Receives No Objection Letter from Health Canada
April 12, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, April 12, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing...
XORTX Announces Grant of US Patent
April 07, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, April 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing...
XORTX Files IND with US FDA
March 31, 2022 07:00 ET
|
XORTX Therapeutics Inc.
● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX I...